Combined therapy of L1210 leukemia with cyclophosphamide and lycurim.
The authors treated DBA/2 mice with L1210 leukemia with cyclophosphamide (CY) plus lycurim (LY), both alkylating agents. There was established a dose-dependent antitumor effect after early single treatment with CY and LY. Sequentional combined treatment with CY and LY induced an enhancement or synergism in therapeutic effect of drugs, more related to the doses used than to the sequence of drug administration. The optimal synergistic effect, as well as "cure" of treated animals were observed when both drugs were used in doses close to LD10.
D000477:Alkylating Agents / Q000494:pharmacology; D000818:Animals; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004896:Erythritol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D007928:Lethal Dose 50; D007939:Leukemia L1210 / Q000188:drug therapy*; D051379:Mice
D000477:Alkylating Agents; D003520:Cyclophosphamide; D004896:Erythritol; C000288:ritrosulfan